Diabetes, weight loss drug companies growth far from over, says ClearBridge analyst

ClearBridge research analyst Marshall Gordon sits down with InvestmentNews anchor Gregg Greenberg to discuss the rise of new diabetes and weight-loss drugs, as well as the best ways to invest in this burgeoning sector.
More: IN THE NASDAQ
Knighthead Insurance Group CEO highlights successful product rollout

Knighthead Insurance Group CEO highlights successful product rollout

Here’s what’s behind the boom in derivative income ETFs

Here’s what’s behind the boom in derivative income ETFs

Schwab Center strategist offers outlook for inflation, jobs and stocks

Schwab Center strategist offers outlook for inflation, jobs and stocks